Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077455 | 0.87 | TP53 (0.46) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6076633 | 0.83 | EPHX2 (0.47) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6077405 | 0.82 | TP53 (0.44) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6077095 | 0.77 | TP53 (0.47) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6075621 | 0.77 | TP53 (0.49) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6077783 | 0.76 | ALDH1A1 (0.43) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6076005 | 0.76 | ALDH1A1 (0.58) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6077211 | 0.76 | TP53 (0.46) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL6076341 | 0.75 | TP53 (0.50) | TP53ALDH1A1RAB9AMAPTNPC1 | |
| SCHEMBL24667463 | 0.75 | ALDH1A1 (0.69) | TP53ALDH1A1RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | claimed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | claimed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | claimed |
| US-7098247-B2 | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1572625-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052838-A1 | ARYLENE-CARBOXYLIC ACID (2-AMINO-PHENYL)-AMIDE DERIVATIVES AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138270-A1 | Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives | MKI67, API5, ACIN1 | TP53 107/4885ALDH1A1 95/4885RAB9A 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.